Exposure to phages has little impact on the evolution of bacterial antibiotic resistance on drug concentration gradients
Version of Record online: 2 JAN 2014
© 2013 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Volume 7, Issue 3, pages 394–402, March 2014
How to Cite
Zhang, Q.-G. (2014), Exposure to phages has little impact on the evolution of bacterial antibiotic resistance on drug concentration gradients. Evolutionary Applications, 7: 394–402. doi: 10.1111/eva.12136
- Issue online: 17 MAR 2014
- Version of Record online: 2 JAN 2014
- Manuscript Accepted: 31 OCT 2013
- Manuscript Received: 26 JUN 2013
- National Natural Science Foundation of China. Grant Numbers: 31222010, 31030014, 31121003, 111 project B13008
- 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Current Opinion in Microbiology 9:461–465.
- 2011. Persistence of antibiotic resistance in bacterial populations. FEMS Microbiology Reviews 35:901–911. , and
- 1995. Site directed chromosomal marking of a fluorescent pseudomonad isolated from the phytosphere of sugar beet; Stability and potential for marker gene transfer. Molecular Ecology 4:755–763. , , , , and
- 1997. Selective compartments for resistant microorganisms in antibiotic gradients. BioEssays 19:731–736. , and
- 1997. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends in Microbiology 5:268–271. , and
- 2008. Selection: the Mechanism of Evolution. 2nd edn. Oxford University Press, Oxford.
- 2000. Linking genetic change to community evolution: insights from studies of bacteria and bacteriophage. Ecology Letters 3:362–377. , and
- 1999. Epistatic interactions can lower the cost of resistance to multiple consumers. Evolution 53:292–295. , , and
- 2007. Experimental coevolution with bacteria and phage: the Pseudomonas fluorescens-Φ2 model system. Infection, Genetics and Evolution 7:547–552. , , , and
- 2005. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. Journal of Antimicrobial Chemotherapy 55:6–9. , and
- 2012. Bacteria–virus coevolution. In O. S. Soyer ed. Evolutionary Systems Biology, pp. 347–370. Springer, New York. , and .
- 2002. Antagonistic coevolution between a bacterium and a bacteriophage. Proceedings of the Royal Society of London Series B-Biological Sciences 269:931–936. , and
- 2006. Antagonistic coevolution with parasites increases the cost of host deleterious mutations. Proceedings of the Royal Society of London Series B-Biological Sciences 273:45–49. , , , , and
- 2008. Bacteriophage therapy and the mutant selection window. Antimicrobial Agents and Chemotherapy 52:4344–4350. , and
- 2011. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiology Reviews 35:977–991. , and
- 2001. Phages and their application against drug-resistant bacteria. Journal of Chemical Technology and Biotechnology 76:689–699. , , , and
- 2003. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resistance Update 6:137–145. , , and
- 2009. Side effects of antibiotics on genetic variability. FEMS Microbiology Reviews 33:531–538. , and
- 2007. The R book. John Wiley & Sons Ltd, Chichester.
- 1995. Failure of drug penetration and acquisition of drug-resistance in chronic tuberculous empyema. Tubercle and Lung Disease 76:463–467. , , , and
- 2004. Rifampicin resistance and its fitness cost in Enterococcus faecium. Journal of Antimicrobial Chemotherapy 53:203–207. , , , and
- 2012. Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage. Evolutionary Applications 5:583–592. , , and
- 2009. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. Journal of Infectious Diseases 200:390–398. , , , , , , et al.
- 2008. Coevolution drives temporal changes in fitness and diversity across environments in a bacteria-bacteriophage interaction. Evolution 62:1830–1839. , , , and
- 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944–1946. , , , , , and
- 2012. Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells. Physical Review Letters 109:088101. , , and
- 2012. Therapeutic antimicrobial peptides may compromise natural immunity. Biology Letters 8:416–418. , and
- 2013. Rapidly fluctuating environments constrain coevolutionary arms races by impeding selective sweeps. Proceedings of the Royal Society of London Series B-Biological Sciences 280:20130937. , , , and
- 2007. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Antimicrobial Agents and Chemotherapy 51:3642–3649. , , , and
- 2012. On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient. Proceedings of the National Academy of Sciences of the United States of America 109:10775–10780. , , and
- 2010. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Molecular Cell 37:311–320. , , and
- 2012. The costs of evolving resistance in heterogeneous parasite environments. Proceedings of the Royal Society of London Series B-Biological Sciences 279:1896–1903. , , , and
- 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends in Biotechnology 28:591–595. , and
- 2010. Phage therapy in clinical practice: treatment of human infections. Current Pharmaceutical Biotechnology 11:69–86. , , , , , , and
- 1991. Long-term experimental evolution in Escherichia coli. I. adaptation and divergence during 2,000 generations. American Naturalist 138:1315–1341. , , , and
- 1996. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. American Naturalist 147:881–898. , and
- 2000. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985–997. , , and
- 2008. Increasing productivity accelerates host-parasite coevolution. Journal of Evolutionary Biology 21:853–860. , and
- 2009. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proceedings of the National Academy of Sciences of the United States of America 106:12025–12030. , , , , , , et al.
- 2010. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nature Reviews Genetics 11:405–414. , , , and
- 2002. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Molecular Microbiology 46:355–366. , , , and
- 2005. Antibiotic cycling: more than it might seem? Journal of Antimicrobial Chemotherapy 55:1–5.
- 2010. Bacteriophage applications: where are we now? Letters in Applied Microbiology 51:363–369. , , , , and
- 2005. The effect of migration on local adaptation in a coevolving host-parasite system. Nature 437:253–256. , , and
- 2008. Tissue concentrations: do we ever learn? Journal of Antimicrobial Chemotherapy 61:235–237. , , , , , and
- 2005. Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrobial Agents and Chemotherapy 49:5081–5091. , , , and
- 2006. Experimental evolution of resistance to an antimicrobial peptide. Proceedings of the Royal Society of London Series B-Biological Sciences 273:251–256. , , and
- 2007. Source-sink dynamics shape the evolution of antibiotic resistance and its pleiotropic fitness cost. Proceedings of the Royal Society of London Series B-Biological Sciences 274:2351–2356. , , and
- 2010. Hypermutability and compensatory adaptation in antibiotic-resistant bacteria. American Naturalist 176:303–311. , , and
- 2011. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharmaceutical Research 28:934–937. , , , , , , et al.
- R Development Core Team 2011. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
- 1996. Physical and genetic map of the Pseudomonas fluorescens SBW25 chromosome. Molecular Microbiology 19:521–533. , and
- 2009. Evolutionary biology and the avoidance of antimicrobial resistance. Evolutionary Applications 2:40–51. , and
- 2011. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 108:10871–10877. , , and
- 1997. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proceedings of the Royal Society of London Series B-Biological Sciences 264:1287–1291. , , and
- 2001. Bacteriophage therapy. Annual Review of Microbiology 55:437–451.
- 2004. Old dogma, new tricks - 21st century phage therapy. Nature Biotechnology 22:31–36.
- 2012. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nature Genetics 44:101–U140. , , , , , and
- 2009. Dispersal and natural enemies interact to drive spatial synchrony and decrease stability in patchy populations. Ecology Letters 12:1194–1200. , , and
- 2009. The cost of multiple drug resistance in Pseudomonas aeruginosa. Journal of Evolutionary Biology 22:997–1003. , , and
- 2012. General and inducible hypermutation facilitate parallel adaptation in Pseudomonas aeruginosa despite divergent mutation spectra. Proceedings of the National Academy of Sciences of the United States of America 109:13680–13685. , and
- 2006. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111–114. , , , and
- 2012. Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evolutionary Applications 5:575–582. , and